Cisplatin gsh

WebJun 20, 2024 · We propose here a new mechanism of cisplatin resistance mediated by glutathione transferase (GST) P1-1, as a cisplatin-binding protein. Our results show that … WebFeb 16, 2024 · severe or ongoing nausea and vomiting; vision problems, pain behind your eyes; hearing problems, ringing in your ears; pain, redness, swelling, or skin changes …

The role of GSH in MRP-mediated CDDP transport. De novo

WebApr 1, 2016 · Cisplatin is also inactivated by glutathione-s-transferase, which add a glutathione (GSH) to cisplatin. The conjugated cisplatin-GSH is then exported via the MRP2 transporters. Cisplatin is also exported by ATP7A and ATP7B. Inactivation of cisplatin can also result from binding metallothionein proteins (MT). WebHerein, we report that the SLC7A11-AS1 and xCT are involved in cisplatin resistanc … Functional role of the SLC7A11-AS1/xCT axis in the development of gastric cancer cisplatin-resistance by a GSH-dependent mechanism Free Radic Biol Med. 2024 Mar 30;S0891-5849(22) 00129-0. doi ... inc 3 download https://brainstormnow.net

Functional role of the SLC7A11-AS1/xCT axis in the development …

WebJul 20, 2024 · Platinum-based chemotherapy is widely used to treat various cancers. However, exogenous platinum is likely to cause severe side effects and drug resistance induced by upregulated glutathione (GSH) in cancer cells poses a threat to the management of cancer progression and recurrence. WebThree mechanisms have been proposed for the role of glutathione (GSH) in regulating cisplatin (CDDP) sensitivities that affects its ultimate cell-killing ability: (i) GSH may … WebJan 15, 2024 · Cisplatin is a chemotherapeutic agent widely used to treat various malignancies, and its application is greatly limited due to its nephrotoxicity, including its onset of acute kidney injury (AKI) [ 1 ]. Undoubtedly, effective drugs to prevent cisplatin-induced AKI (Cis-AKI) in clinical practice are in urgent demand. inc 3 life goal red flags

Effects of acute in vivo cisplatin and selenium treatment on ...

Category:Doseâ Dependent Protection by Lipoic Acid against …

Tags:Cisplatin gsh

Cisplatin gsh

Predictive and prognostic significance of glutathione levels and …

WebOct 1, 2024 · In brief, the reduction of GSH can rescue the inactivation of cisplatin, increase sensitivity of cancer cells to platinum drugs. As shown in Fig. S1A (Supporting information), CDDP-OH was firstly synthesized through oxidizing cisplatin by H 2 O 2 using the method previously reported [21]. WebApr 25, 2024 · Cisplatin accumulates in the mitochondria of renal epithelial cells during excretion of cisplatin metabolites through renal tubules and further forms a cisplatin–glutathione (GSH) complex, which ...

Cisplatin gsh

Did you know?

WebNov 27, 2024 · It is well established that one of the main factors that promote intracellular cisplatin detoxification is GSH, since it can bind covalently to the drug and prevent it to … WebFeb 12, 2024 · Cisplatin, [Pt (NH 3) 2 Cl 2] (CDDP), is a potent chemotherapeutic agent used for several types of cancer, e.g. carcinoma of the ovary, testicle, head and neck, bones, brain, lymph node, and skin. 1,2 CDDP still represents the elective cytotoxic agent for the treatment of the carcinoma of the ovary, which is the leading cause of death …

WebDec 15, 2015 · HCT116 colon carcinoma was selected as cancer cell prototypes that overexpress GSH. 49 Cells were incubated for 6 hours with CDDP-containing samples (or controls) in order to mimic the clinically used intravenous (iv) infusion of cisplatin, and then further incubated for 66 hours in fresh media to assess the cytotoxicity profiles over a … WebEbselen is a seleno-organic compound with documented cytoprotective properties. Little work has been done, however, demonstrating ebselen's cytoprotective prop

WebAug 10, 2024 · Overall, our data suggest that cisplatin treatment could positively select cancer cells which are independent from GSH for the maintenance of redox balance, and thus less sensitive to cisplatin-induced oxidative stress, opening new scenarios for the GSH pathway as a therapeutic target in HGSOC. Keywords: WebPubMed Central (PMC)

WebFeb 1, 2012 · Recently, Volckova, et al. [17] used a variety of physical techniques to show that GSH rapidly reduces iproplatin, 2, to produce cis -di (isopropylamine)chloro-glutathionatoplatinum (II) which has the thiolate of a GSH molecule bound to Pt (II).

WebSep 15, 2024 · Cisplatin Injection (cisplatin injection (cisplatin (cisplatin injection) injection) ) is a sterile aqueous solution, available in 50, 100 and 200 mL multiple dose … inc 3 formatWebMar 13, 2006 · Cisplatin is one of the most widely used chemotherapeutic drugs for treating cancer. Initially, platinum-based therapies are very effective in treating a wide array of cancers; however, recurrence and … inclined dumbbell flyWebIndeed, GSH can bind cisplatin forming cisplatin-GSH adducts which are exported from the cells through the multidrug resistance protein-2 (MRP-2) efflux pump, thus reducing the intracellular ... inclined dumbellsWebCisplatin is a platinum-based agent whose nephrotoxicity is thought related to the chloride in the cis position. Cisplatin gains entry into tubular cells via uptake by the OCT-2 … inc 3WebApr 1, 2024 · The therapeutic efficacy of cisplatin has been restricted by drug resistance of cancers. Intracellular glutathione (GSH) detoxification of cisplatin under the catalysis of … inclined elevator standards meaningWebOxidative stress caused by cisplatin, evidenced by increases in kidney tissues malondialdehyde (MDA) content, cytochrome P450 E1 (CYP2E1), renal 4-hydroxynonenal (4-HNE) levels and decreases of glutathione (GSH) and superoxide dismutase (SOD) contents, was significantly ameliorated by AGBE pretreatment. inc 3000Web(GSH) transferase activity of GST P1-1. Instead, GST P1-1 sequesters and inactivates cisplatin with the aid of 2 solvent-accessible cysteines, resulting in protein subunits cross-linking, while maintaining its GSH-conjugation activity. Furthermore, it is well known that GST P1-1 binding to the c-Jun N-terminal kinase (JNK) inhibits JNK phosphory- inc 3 form